Breadcrumb Navigation

Melanom: A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma: Substudy 02C

Stadium/Indikation inkl. Kurzinfo

Melanom – 1st line

Resezierbares Stadium IIIB-IIID
Neoadjuvante Therapie

Anti-PD1 + anti-TIGIT vs Anti-PD1 + oncolytische Virotherapie vs Anti-PD1 Anschliessende adjuvante anti-PD1 Therapie

Kurztitel

Merck MK3475
Substudy 02C
(UmbrellaTrial)
NCT04303169

Offizieller Titel

A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma: Substudy 02C

PI

Prof. Reinhard Dummer

Zuständige Ärztin

Corinne Eggenschwiler

Tel. +41 43 253 03 96

Behandelnder Fachbereich

Dermatologische Klinik